Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 819-558-9 | CAS number: 2020359-04-8
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
ACD/ADME predicted data indicated that:(1)the compound could be absorbed in small intestinewith a low absorption rate,(2)it may pass the BBB easily,(3)it may have a moderate oral bioavailability between 30% and 70%,(4)it could bind with plasma proteins with a high binding ratio of 98%,(5)it might be an inhibitor of P-gp, and(6)it would not be an inhibitor of CYP450 and could be metabolized into hydroxyl metabolites. The DS/ADMET calculated data suggested:(1)the compound could pass the BBB;(2)it could be absorbed in small intestine;(3)it would not be an inhibitor of CYP450 2D6;(4)its binding ratio on plasma protein would be more than 95%.
In combination of predicted data from both softwares and corresponding literature reported pharmacokinetics of the compound Fluorene, it was predicted that1-(9,9-dibutyl-9H-fluoren-2-yl)-2-methyl-2-morpholinopropan-1-one could be absorbed in small intestinewith a low absorption rate, and its oral bioavailability would be at a middle level between 30% and 70%. It may pass the BBB easily to have contribution in brain. Its binding ratio on plasma proteins would be at a high level more than 95% but less than 99%. It might be an inhibitor of P-gp. The compound would not be an inhibitor of CYP450 and could be metabolized by corresponding enzymes. Since the compound contains the condensed ring of fluorene, it could be transferred to phenolic metabolites by phase I metabolism and even to glucoside metabolites by further phase II metabolismin vivo. These metabolites would have increased water solubility favorable for their excretion via the urine. Furthermore, 1-(9,9-dibutyl-9H-fluoren-2-yl)-2-methyl-2-morpholino-propan-1-one might also be excreted directly via the urine or feces, since the compound may have a very low absorption rate in intestine.Key value for chemical safety assessment
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
